Myelodysplastic syndrome with excess blasts Treatment

Supportive Care and Blood Transfusions

One of the most common interventions for patients with MDS-EB involves supportive care, which focuses on replacing the blood cells that the body cannot produce on its own. When someone has severe anemia due to insufficient red blood cells, they may need regular red blood cell transfusions. These transfusions deliver healthy red blood cells that carry oxygen throughout the body, helping to relieve fatigue, weakness, and shortness of breath.4

Similarly, patients who have very low platelet counts may receive platelet transfusions to prevent dangerous bleeding. Modern practice recommends using leukocyte-depleted blood products, which means the blood has been specially processed to remove white blood cells. This approach reduces the risk of fever reactions after transfusion, prevents the body from developing resistance to platelet transfusions, and helps avoid transmission of certain viral infections. While transfusions provide temporary relief, they do not address the underlying problem in the bone marrow.4

Hypomethylating Agents

Two medications called hypomethylating agents have become standard therapy for many patients with MDS-EB. These drugs, azacitidine and decitabine, work by affecting how genes are expressed in bone marrow cells without changing the DNA sequence itself. This process, called DNA methylation, influences whether certain genes are turned on or off. In myelodysplastic syndromes, abnormal methylation patterns contribute to the disease.4

Azacitidine and decitabine help restore more normal patterns of gene activity, which can improve how bone marrow cells develop and function. These medications are particularly useful for older patients who may not tolerate aggressive chemotherapy well. They can be given as injections under the skin or through intravenous infusion. The treatment typically continues over several months, and not everyone responds in the same way. Some patients experience improvement in blood counts and reduced need for transfusions, while others may see stabilization of their disease.4

Chemotherapy

For patients whose myelodysplastic syndrome is progressing toward acute leukemia, or those who already have high numbers of blast cells, doctors may recommend cytotoxic chemotherapy. This type of treatment uses powerful medications to kill rapidly dividing cells. The most common combination includes cytarabine, which interferes with DNA synthesis, plus an anthracycline antibiotic that also disrupts DNA function in cancer cells.4

While this approach can be effective, it yields complete response rates of only 30% to 40% in MDS patients. The treatment can cause significant side effects, particularly in older adults, including profound drops in all blood cell counts, increased infection risk, mouth sores, nausea, and hair loss. Recovery from chemotherapy can take weeks. For these reasons, intensive chemotherapy is generally reserved for younger, otherwise healthy patients who can withstand the rigors of treatment.4

Lenalidomide

A medication called lenalidomide has been approved specifically for certain patients with myelodysplastic syndromes. This drug belongs to a class called immunomodulators, meaning it affects the immune system and has multiple mechanisms of action. Lenalidomide is particularly effective in patients whose bone marrow cells show a specific genetic abnormality called deletion 5q, where part of chromosome 5 is missing. In these individuals, lenalidomide can dramatically reduce or eliminate the need for red blood cell transfusions.4

The medication comes in capsule form and is taken daily. Common side effects include low blood cell counts (especially neutrophils and platelets), fatigue, diarrhea, itching, and rash. Patients need regular blood monitoring while taking this medication. Lenalidomide can cause birth defects, so strict pregnancy prevention measures are required for anyone who could become pregnant or father a child.4

Stem Cell Transplantation

The only treatment approach that can potentially cure myelodysplastic syndromes is allogeneic stem cell transplantation, also called bone marrow transplant. In this procedure, a patient's diseased bone marrow is destroyed using high doses of chemotherapy and sometimes radiation. Then, healthy stem cells from a matched donor are infused into the patient's bloodstream. These donor cells travel to the bone marrow and begin producing normal blood cells.1

Stem cell transplantation carries substantial risks, particularly for older patients or those with other health conditions. Complications can include graft-versus-host disease, where the donor immune cells attack the patient's own tissues, as well as serious infections, organ damage, and treatment-related mortality. Because MDS-EB primarily affects people over 60 years old, many patients are not candidates for this intensive procedure. However, for younger, fit individuals with high-risk disease, transplantation offers the best chance for long-term survival.1

Understanding Clinical Trial Phases

Clinical trials follow a structured process with different phases. Phase I trials primarily assess safety, determining what dose of a new drug can be given without causing unacceptable side effects. These studies involve small numbers of patients. Phase II trials evaluate whether the treatment shows signs of effectiveness against the disease while continuing to monitor safety. Phase III trials compare the new treatment directly against current standard therapy, often involving hundreds of patients at multiple medical centers. These large studies determine whether new treatments truly improve outcomes compared to existing options.5

Novel Medications Under Investigation

Several promising medications are currently being studied in clinical trials for myelodysplastic syndromes. One example is luspatercept, known by the code name ACE-536, which is being tested in a Phase 3 trial. This medication works differently than traditional therapies by promoting the maturation of red blood cells in the bone marrow. The trial compares luspatercept against epoetin alfa (a growth factor that stimulates red blood cell production) in patients with lower or intermediate-risk MDS who have anemia but do not require regular transfusions. The study aims to determine which treatment better controls anemia and improves quality of life.2

Another investigational approach involves an oral combination medication called ASTX030, which contains cedazuridine and azacitidine. Since azacitidine has traditionally been given by injection, an effective oral version would be much more convenient for patients. This multi-phase trial includes dose-escalation studies to find the right oral dose, followed by a comparison between the oral combination and standard injected azacitidine. The oral medication could allow patients to receive treatment at home rather than visiting a clinic for injections, potentially improving quality of life.2

Targeting Specific Molecular Pathways

Scientists have identified various molecular abnormalities in myelodysplastic syndrome cells that can serve as targets for new therapies. Many patients with MDS have mutations in genes that control how DNA is modified or how RNA is processed. Drugs targeting these specific genetic changes are under development. For instance, some experimental therapies focus on mutations in genes like SF3B1 or TP53, which are frequently found in MDS cells and influence how the disease behaves.6

The goal of these targeted approaches is to interfere with the abnormal processes driving the disease while causing less harm to normal cells. This precision medicine strategy represents a shift from traditional chemotherapy, which affects all rapidly dividing cells, toward treatments that home in on the molecular defects specific to each patient's disease. As genetic testing becomes more sophisticated, doctors may eventually be able to match individual patients with therapies designed to target their particular genetic abnormalities.6

Participation and Eligibility

Clinical trials for myelodysplastic syndromes are conducted at medical centers throughout the United States, Europe, and other regions. Each trial has specific eligibility criteria based on factors such as disease subtype, previous treatments received, blood counts, organ function, and overall health status. Some trials focus on patients who have never received treatment, while others enroll those whose disease has not responded to standard therapies or has relapsed after initial treatment.2

Patients considering clinical trial participation should have detailed discussions with their healthcare team about potential benefits and risks. Trials may offer access to promising new treatments before they become widely available, but they also involve uncertainty about effectiveness and possible unknown side effects. Many patients find participation rewarding, knowing they are contributing to medical knowledge that may help future patients, even if they do not personally benefit.7